eurochemische Modulation von Exekutiv- und Gedächtnisfunktione
- Conditions
- Progressive cognitive decline in physiological aging
- Registration Number
- EUCTR2005-000434-21-DE
- Lead Sponsor
- Kognitive Neurologie, Institut für Medizin, Forschungszentrum Jülich
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
-Healthy subjects age range 18-75 years
-Right-handed
-fluent in German language
-capable of informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
-neurological or psychiatric disease
-any severe medical condition
-asthma bronchiale, suspicion of melanoma, gangrene, coronary heart disease, mechanical
obstipation of bowels or urinary pathways, glaucoma, hyperthyreosis, cardial arrhythmia, diarrhea
-known allergic reactions to Sulfite, Glycopyrroniumbromid, Levodopa/Carbidopa,
Physostigminsalicylate
-regular intake of centrally active pharmacological agents
-intake of MAO-A-inhibitors or other cholinesterase-inhibitors
-pregnancy or lactation
-incorporated ferromagnetic objects (e.g. pace-maker, intrauterine-devices, endoprothesis of the joints, tattoos, etc.)
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method